Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion. Despite ...

KBC Group NV increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 78.2% during the 4th ...

Rhythm Pharmaceuticals reports estimated $42 million Q4 and $130 million full year 2024 revenues for IMCIVREE, with clinical trial advancements. Rhythm Pharmaceuticals, Inc. reported preliminary ...

Rhythm Pharmaceuticals, Inc. BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The fireside chat will be webcasted and available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be ...

Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be ...